Catheter Precision Stock-Based Compensation Growth & History (VTAK)
Catheter Precision's stock-based compensation was $338,000 for fiscal 2025.
View full Catheter Precision company overviewCatheter Precision annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $338,000 | $284,000 | +525.93% |
| 2024 | 2024-12-31 | $54,000 | −$1.2M | −95.56% |
| 2023 | 2023-12-31 | $1.2M | $770,000 | +172.26% |
| 2022 | 2022-12-31 | $447,000 | −$1.8M | −80.02% |
| 2021 | 2021-12-31 | $2.2M | −$1.8M | −45.20% |
| 2020 | 2020-12-31 | $4.1M | −$19.5M | −82.66% |
| 2019 | 2019-12-31 | $23.5M | $8.8M | +59.85% |
| 2018 | 2018-12-31 | $14.7M | $2.0M | +15.91% |
| 2017 | 2017-12-31 | $12.7M | — | — |
Catheter Precision quarterly stock-based compensation
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $266,000 | $168,000 | +171.43% |
| Q1 2026 | 2026-03-31 | $64,000 | −$27,000 | −29.67% |
| Q4 2025 | 2025-12-31 | $79,000 | $61,000 | +338.89% |
| Q3 2025 | 2025-09-30 | $70,000 | $53,000 | +311.76% |
| Q2 2025 | 2025-06-30 | $98,000 | $85,000 | +653.85% |
| Q1 2025 | 2025-03-31 | $91,000 | $85,000 | +1416.67% |
| Q4 2024 | 2024-12-31 | $18,000 | — | — |
| Q3 2024 | 2024-09-30 | $17,000 | $15,000 | +750.00% |
| Q2 2024 | 2024-06-30 | $13,000 | −$161,000 | −92.53% |
| Q1 2024 | 2024-03-31 | $6,000 | −$1.4M | −99.57% |
| Q3 2023 | 2023-09-30 | $2,000 | −$72,000 | −97.30% |
| Q2 2023 | 2023-06-30 | $174,000 | $48,000 | +38.10% |
| Q1 2023 | 2023-03-31 | $1.4M | $1.2M | +744.85% |
| Q4 2022 | 2022-12-31 | $82,000 | −$188,000 | −69.63% |
| Q3 2022 | 2022-09-30 | $74,000 | −$28,000 | −27.45% |
| Q2 2022 | 2022-06-30 | $126,000 | −$570,000 | −81.90% |
| Q1 2022 | 2022-03-31 | $165,000 | −$1.0M | −85.89% |
| Q4 2021 | 2021-12-31 | $270,000 | −$768,000 | −73.99% |
| Q3 2021 | 2021-09-30 | $102,000 | −$862,000 | −89.42% |
| Q2 2021 | 2021-06-30 | $696,000 | −$337,000 | −32.62% |
| Q1 2021 | 2021-03-31 | $1.2M | $122,000 | +11.65% |
| Q4 2020 | 2020-12-31 | $1.0M | −$351,000 | −25.27% |
| Q3 2020 | 2020-09-30 | $964,000 | −$6.3M | −86.75% |
| Q2 2020 | 2020-06-30 | $1.0M | −$6.1M | −85.52% |
| Q1 2020 | 2020-03-31 | $1.0M | −$6.7M | −86.48% |
| Q4 2019 | 2019-12-31 | $1.4M | −$6.6M | −82.67% |
| Q3 2019 | 2019-09-30 | $7.3M | $5.8M | +381.92% |
| Q2 2019 | 2019-06-30 | $7.1M | $2.5M | +52.39% |
| Q1 2019 | 2019-03-31 | $7.7M | $7.2M | +1378.05% |
| Q4 2018 | 2018-12-31 | $8.0M | — | — |
| Q3 2018 | 2018-09-30 | $1.5M | $941,000 | +165.38% |
| Q2 2018 | 2018-06-30 | $4.7M | — | — |
| Q1 2018 | 2018-03-31 | $524,000 | — | — |
| Q3 2017 | 2017-09-30 | $569,000 | — | — |
Catheter Precision stock-based compensation trends
Over the last five fiscal years, Catheter Precision's stock-based compensation decreased from $4.1M to $338,000, a change of −$3.7M. The latest reported quarter, Q2 2026, shows $266,000.
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Catheter Precision source filings ↗